- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03281330
Effect of Motor Entrainment to Auditory Cues and Music During Walking on Quality of Movement and Perceived Fatigue in Persons With Multiple Sclerosis (PwMS)
August 2, 2018 updated by: Peter Feys, Hasselt University
The study investigates the effect of different conditions of auditory cueing and music on walking quality and perceived fatigue in persons with multiple sclerosis compared to healthy controls.
The study extends over a four session period, each session lasting maximally 1h30 minutes The experimental conditions include participants walking to music and metronome (at different tempi) for 3minutes and 15 seconds per condition, with a rest period of 3 minutes in between each condition.
Non-invasive equipment will be used.
participants are equipped with sensors (watch-like straps at the wrists, ankles and across the chest) and are given wireless headphones.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Observational
Enrollment (Actual)
60
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Gent, Belgium
- University of Ghent
-
Melsbroek, Belgium
- Nationaal Multiple Sclerose Center
-
Overpelt, Belgium
- Revalidatie & MS Centrum Overpelt
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 80 years (ADULT, OLDER_ADULT)
Accepts Healthy Volunteers
N/A
Genders Eligible for Study
All
Sampling Method
Probability Sample
Study Population
persons with Multiple Sclerosis and healthy volonteers
Description
Inclusion Criteria:
- diagnosis of MS of >1 year,
- no relapse in the last 1 month,
- ability to walk for 12 minutes without interruption,
- an average usual walking speed between the range of 0.4 and 1.2 m/s.
Exclusion Criteria:
- cognitive impairment hindering the understanding and execution of the experimental procedures
- pregnancy
- hearing impairment
- amusia
- beat deafness
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Healthy controls
|
the effect of different conditions of auditory cueing and music on walking quality and perceived fatigue in persons with multiple sclerosis compared to healthy controls
|
persons with Multiple Sclerosis
|
the effect of different conditions of auditory cueing and music on walking quality and perceived fatigue in persons with multiple sclerosis compared to healthy controls
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Spatio-temporal parameters of gait
Time Frame: day 1
|
Participants wear portable APDM sensors.
These sensors are activated during the walking, and record the spatio-temporal parameters of gait.
|
day 1
|
Spatio-temporal parameters of gait
Time Frame: week 1
|
Participants wear portable APDM sensors.
These sensors are activated during the walking, and record the spatio-temporal parameters of gait.
|
week 1
|
Spatio-temporal parameters of gait
Time Frame: week 2
|
Participants wear portable APDM sensors.
These sensors are activated during the walking, and record the spatio-temporal parameters of gait.
|
week 2
|
Spatio-temporal parameters of gait
Time Frame: week 3
|
Participants wear portable APDM sensors.
These sensors are activated during the walking, and record the spatio-temporal parameters of gait.
|
week 3
|
Parameter's of sychronisation
Time Frame: day 1
|
Participants have two light ipods attached on their ankles- these are a part of the D-jogger system.
The system is activated during the walking, and logs the synchronization parameters
|
day 1
|
Parameter's of sychronisation
Time Frame: week 1
|
Participants have two light ipods attached on their ankles- these are a part of the D-jogger system.
The system is activated during the walking, and logs the synchronization parameters
|
week 1
|
Parameter's of sychronisation
Time Frame: week 2
|
Participants have two light ipods attached on their ankles- these are a part of the D-jogger system.
The system is activated during the walking, and logs the synchronization parameters
|
week 2
|
Parameter's of sychronisation
Time Frame: week 3
|
Participants have two light ipods attached on their ankles- these are a part of the D-jogger system.
The system is activated during the walking, and logs the synchronization parameters
|
week 3
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
subjective physical /mental fatigue
Time Frame: day 1
|
After each experimental condition, the participant is asked 'how tired do you feel in your body on a scale of 0 to 10, 0 being not tired at all and 10 being exhausted'
|
day 1
|
subjective physical /mental fatigue
Time Frame: week 1
|
After each experimental condition, the participant is asked 'how tired do you feel in your body on a scale of 0 to 10, 0 being not tired at all and 10 being exhausted'
|
week 1
|
subjective physical /mental fatigue
Time Frame: week 2
|
After each experimental condition, the participant is asked 'how tired do you feel in your body on a scale of 0 to 10, 0 being not tired at all and 10 being exhausted'
|
week 2
|
physical /mental fatigue
Time Frame: week 3
|
After each experimental condition, the participant is asked 'how tired do you feel in your body on a scale of 0 to 10, 0 being not tired at all and 10 being exhausted'
|
week 3
|
motivation
Time Frame: day 1
|
he participants is asked: 'how motivating was it to walk to the last particular stimuli (in the metronome condition)/Song (in the music condition) on a scale of 0-5. ) being not motivating at all and 5 being very motivating'.
|
day 1
|
motivation
Time Frame: week 1
|
he participants is asked: 'how motivating was it to walk to the last particular stimuli (in the metronome condition)/Song (in the music condition) on a scale of 0-5. ) being not motivating at all and 5 being very motivating'.
|
week 1
|
motivation
Time Frame: week 2
|
he participants is asked: 'how motivating was it to walk to the last particular stimuli (in the metronome condition)/Song (in the music condition) on a scale of 0-5. ) being not motivating at all and 5 being very motivating'.
|
week 2
|
motivation
Time Frame: week 3
|
he participants is asked: 'how motivating was it to walk to the last particular stimuli (in the metronome condition)/Song (in the music condition) on a scale of 0-5. ) being not motivating at all and 5 being very motivating'.
|
week 3
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (ACTUAL)
February 1, 2017
Primary Completion (ACTUAL)
May 30, 2018
Study Completion (ACTUAL)
June 30, 2018
Study Registration Dates
First Submitted
September 11, 2017
First Submitted That Met QC Criteria
September 11, 2017
First Posted (ACTUAL)
September 13, 2017
Study Record Updates
Last Update Posted (ACTUAL)
August 3, 2018
Last Update Submitted That Met QC Criteria
August 2, 2018
Last Verified
August 1, 2018
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- B67021629797
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
UNDECIDED
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Multiple Sclerosis
-
University Hospital, Basel, SwitzerlandSwiss National Science FoundationRecruitingMultiple Sclerosis (MS) | Relapsing-remitting Multiple Sclerosis (RRMS) | Secondary-progressive Multiple Sclerosis (SPMS) | Primary Progressive Multiple Sclerosis (PPMS)Switzerland
-
University of California, Los AngelesUnknownRelapsing-remitting Multiple Sclerosis | Secondary-progressive Multiple Sclerosis | Primary-progressive Multiple SclerosisUnited States
-
BiogenCompletedMultiple Sclerosis | Relapsing-Remitting Multiple Sclerosis | Secondary Progressive Multiple Sclerosis | Multiple Sclerosis, Primary Progressive | Multiple Sclerosis, Remittent ProgressiveJapan
-
The Cleveland ClinicUniversity Hospitals Cleveland Medical CenterCompletedRelapsing-Remitting Multiple Sclerosis | Secondary Progressive Multiple Sclerosis | Progressive Relapsing Multiple SclerosisUnited States
-
Rigshospitalet, DenmarkOdense University Hospital; Aarhus University Hospital; Hvidovre University Hospital and other collaboratorsActive, not recruitingRelapsing Remitting Multiple Sclerosis | Primary Progressive Multiple Sclerosis | Secondary Progressive Multiple SclerosisDenmark
-
Queen Mary University of LondonTakeda Pharmaceuticals International, Inc.RecruitingRelapsing Remitting Multiple Sclerosis | Primary Progressive Multiple Sclerosis | Secondary Progressive Multiple SclerosisUnited Kingdom
-
University of California, San FranciscoUnited States Department of DefenseRecruitingMultiple Sclerosis, Chronic Progressive | Multiple Sclerosis, Relapsing-Remitting | Multiple Sclerosis (MS) | Multiple Sclerosis Relapse | Multiple Sclerosis, Primary Progressive | Multiple Sclerosis Brain Lesion | Multiple Sclerosis BenignUnited States
-
Icahn School of Medicine at Mount SinaiColumbia University; New York Stem Cell Foundation Research InstituteCompletedClinically Isolated Syndrome | Relapsing-Remitting Multiple Sclerosis | Primary Progressive Multiple Sclerosis | Secondary Progressive Multiple SclerosisUnited States
-
Banc de Sang i TeixitsVall d'Hebron Research Institute (VHIR)CompletedRelapsing-Remitting Multiple Sclerosis | Secondary Progressive Multiple SclerosisSpain
-
BiogenElan PharmaceuticalsCompletedRelapsing-Remitting Multiple Sclerosis | Secondary Progressive Multiple SclerosisUnited States
Clinical Trials on auditory cues and music during walking
-
Hasselt UniversityRevalidatie & MS Centrum Overpelt; National MS Center MelsbroekRecruitingMultiple Sclerosis | Cerebral LesionBelgium
-
The Cleveland ClinicNational Institutes of Health (NIH)WithdrawnGait Disturbance in Multiple Sclerosis PatientsUnited States
-
Superior UniversityRecruitingParkinson DiseasePakistan
-
New York UniversityThe New York Eye & Ear InfirmaryActive, not recruitingHearing Loss, Sensorineural | Vestibular DisorderUnited States
-
Toronto Metropolitan UniversityMitacs; Sonova Canada Inc.; Lucid, Inc.Not yet recruiting
-
Chulalongkorn UniversityCompletedParkinson's DiseaseThailand
-
Lucid, Inc.CompletedMild to Moderate DementiaCanada
-
Ryerson UniversityNot yet recruiting
-
Charite University, Berlin, GermanySana-Klinikum Lichtenberg; Vivantes Klinikum am Urban; Park-Klinik Berlin Weißensee and other collaboratorsRecruiting
-
Institut Claudius RegaudRecruiting